Cost comparison of 111In-DTPA-octreotide scintigraphy and 68Ga-DOTATOC PET/CT for staging enteropancreatic neuroendocrine tumours.
about
Clinical applications of Gallium-68PET tracers for somatostatin receptor imaging of neuroendocrine tumors: current status and review of the literatureA new automated NaCl based robust method for routine production of gallium-68 labeled peptides.Blood transcript analysis and metastatic recurrent small bowel carcinoid management.Searching for primaries in patients with neuroendocrine tumors (NET) of unknown primary and clinically suspected NET: Evaluation of Ga-68 DOTATOC PET/CT and In-111 DTPA octreotide SPECT/CTResults of (68)Gallium-DOTATATE PET/CT Scanning in Patients with Multiple Endocrine Neoplasia Type 1.Comparison of Diagnostic Sensitivity and Quantitative Indices Between (68)Ga-DOTATOC PET/CT and (111)In-Pentetreotide SPECT/CT in Neuroendocrine Tumors: a Preliminary Report.Prospective Study of 68Ga-DOTATATE Positron Emission Tomography/Computed Tomography for Detecting Gastro-Entero-Pancreatic Neuroendocrine Tumors and Unknown Primary SitesProspective of ⁶⁸Ga-radiopharmaceutical development.Diagnostic performance of Gallium-68 somatostatin receptor PET and PET/CT in patients with thoracic and gastroenteropancreatic neuroendocrine tumours: a meta-analysis.Role of PET/CT in the functional imaging of endocrine pancreatic tumors.Somatostatin receptor PET/CT in neuroendocrine tumours: update on systematic review and meta-analysis.Cyclotron production of (68)Ga via the (68)Zn(p,n)(68)Ga reaction in aqueous solution.Role of positron emission tomography imaging in Multiple Endocrine Neoplasia syndromes.Evaluation of (68)Ga-DOTA-TOC PET/CT for the detection of duodenopancreatic neuroendocrine tumors in patients with MEN1.Progress in the formulation and delivery of somatostatin analogs for acromegaly.Splenic scintigraphy for further differentiation of unclear (68) Ga-DOTATOC-PET/CT findings: Strengths and limitations.Potential role of (68)Ga-DOTATOC PET/CT in screening for pancreatic neuroendocrine tumour in patients with von Hippel-Lindau disease.
P2860
Q26849276-3BB03064-D51F-48E9-96E7-E1352E6A87EFQ26992201-4C4F3E06-2218-4662-B806-245CAA0627FEQ33896997-BC4B9617-9872-4551-B082-7BF2061019D4Q34107681-54388B03-A574-4717-A169-B135B4A55BD4Q34503869-E8C3CCD3-01E4-4C9C-9CB7-B2977E56BA6DQ35891227-4E862A9B-9AA0-454E-A241-E8F950F6BFE6Q36241229-9159FEA4-1C78-4BBA-A3B0-319E44234950Q36914468-21E49499-09A8-4516-A04A-E1F1D727A28EQ37435222-D5A710E9-0A76-4716-AFB5-6E79A1BFCA46Q37986605-5CB8E4E0-F318-4B52-B8C4-D8439D847E6BQ37994083-E985902D-C6C6-4BD9-949A-06DDAC7A6555Q38123057-B87A2DE4-9AC5-4DFF-A4F3-A97799142709Q38396735-46E89CD9-A333-4ADF-991F-311ACCD925C5Q38966288-2B4C67A9-FB4B-4CFF-8110-8B0EA57637CEQ40051095-7805E878-1F79-4284-980C-734C58B6D29AQ47928226-CC91325A-56EB-491D-B8B1-08B28F7B07B4Q50239890-09E97E86-7429-4FE7-9015-4C291127BEE6Q52851173-5FF7C0EB-E433-4071-845F-47685CB534B7
P2860
Cost comparison of 111In-DTPA-octreotide scintigraphy and 68Ga-DOTATOC PET/CT for staging enteropancreatic neuroendocrine tumours.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh-hant
name
Cost comparison of 111In-DTPA- ...... reatic neuroendocrine tumours.
@en
Cost comparison of 111In-DTPA- ...... reatic neuroendocrine tumours.
@nl
type
label
Cost comparison of 111In-DTPA- ...... reatic neuroendocrine tumours.
@en
Cost comparison of 111In-DTPA- ...... reatic neuroendocrine tumours.
@nl
prefLabel
Cost comparison of 111In-DTPA- ...... reatic neuroendocrine tumours.
@en
Cost comparison of 111In-DTPA- ...... reatic neuroendocrine tumours.
@nl
P2093
P2860
P1476
Cost comparison of 111In-DTPA- ...... reatic neuroendocrine tumours.
@en
P2093
Alexander Huppertz
Munenobu Nogami
Nils F Schreiter
Ralph Buchert
Ulrich-Frank Pape
Vikas Prasad
Winfried Brenner
P2860
P2888
P356
10.1007/S00259-011-1935-5
P577
2011-09-17T00:00:00Z